N-803 + docetaxel + nivolumab

This is a combination therapy consisting of three agents: - **N-803** is a novel interleukin-15 (IL-15) superagonist complex that directly stimulates CD8+ T cells and natural killer (NK) cells via beta gamma T-cell receptor binding. It consists of an IL-15 mutant bound to an IL‑15 receptor α/IgG1 Fc fusion protein. This design enhances immune cell proliferation and activation while avoiding regulatory T cell stimulation. N‑803 has improved pharmacokinetics and tissue persistence compared to native IL‑15[2][4][6]. Mechanistically, it mimics dendritic cell biology by driving the generation of memory killer T cells trained to recognize cancer cells[4]. It is FDA-approved for BCG-unresponsive non-muscle-invasive bladder cancer but is also being studied in other solid tumors. - **Docetaxel** is a microtubule inhibitor chemotherapy agent that promotes microtubule assembly while inhibiting disassembly, leading to apoptosis in rapidly dividing tumor cells. - **Nivolumab** is a monoclonal antibody checkpoint inhibitor targeting programmed death 1 (PD‑1) on T lymphocytes. By blocking PD‑1 interaction with its ligands PD-L1/PD-L2, it restores anti-tumor immune responses. The rationale for combining these drugs lies in their complementary mechanisms—immune activation by N‑803 and nivolumab alongside direct cytotoxicity from docetaxel—to enhance anti-tumor efficacy beyond what each could achieve alone[1].

Brand names

Anktiva

Other names

IL-15 superagonist complex (N-803)interleukin-15 receptor agonist (N-803)